MAP2K7 and neoplasm: Collectively, these findings suggest that AZD2014, in combination with selumetinib, results in significant anti-tumor activity of RICTOR/KRAS-altered LUAD, through simultaneous blockade of mTORC1/2 and MEK pathways.